GLP-1 Market
LLY $1382.75 ▼ -2.3% NVO $39.43 ▼ -3.1% PFE $28.06 ▼ -1.4% VKTX $26.17 ▼ -2.6% KLRA $11.79 ▼ -3.4% GPCR $17.36 ▼ -4.5% RHHBY $59.52 ▼ -1.2%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Multiple-ascending Doses (MAD) study

Company
Chengdu Zenitar Biomedical Technology Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 19, 2026

Find a Clinical Trial Near Me

See recruiting studies for Multiple-ascending Doses (MAD) study and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07618247

    Single Ascending Doses (SAD) and Multiple Ascending Doses(MAD) Study of IG001119 in Healthy Adult Participants

    Not yet reported Iongen Therapeutics Co., Ltd. 96 participants Est. completion 2027-05-30 2 sites
    Other conditions: Pain
    View official trial listing →
  • Completed NCT NCT05895565

    A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

    Not yet reported Pulmongene Ltd. 29 participants Est. completion 2025-02-07 7 sites
    Other conditions: IPF
    View official trial listing →
  • Completed NCT NCT06082323

    A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers

    Not yet reported Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. 150 participants Est. completion 2025-11-25 1 site
    Other conditions: Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis
    View official trial listing →
  • Not yet recruiting NCT NCT07946783

    A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

    Not yet reported Chengdu Zenitar Biomedical Technology Co., Ltd 103 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Obesity With Cardiovascular Risk Study
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.